CLDX
Celldex Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$39.68
+0.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 112.0K | 1.5M | 7.0M | 6.9M | 2.4M |
| Cost of Revenue | 63.8M | — | 163.6M | 118.0M | 82.3M |
| Gross Profit | (63.7M) | 1.5M | (156.5M) | (111.1M) | (79.9M) |
| Operating Expenses | |||||
| R&D Expense | 278.8M | 245.1M | 163.6M | 118.0M | 82.3M |
| SG&A Expense | 47.1M | 43.8M | 38.5M | 30.9M | 27.2M |
| General & Admin Expense | 47.1M | 43.8M | 38.5M | 30.9M | 27.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (63.8M) | — | (163.6M) | (105.5M) | (74.1M) |
| Total Operating Expenses | 262.2M | 288.9M | 38.5M | 43.4M | 35.3M |
| Cost and Expenses | 326.0M | 288.9M | 202.1M | 161.4M | 117.6M |
| Operating Income (EBIT) | (325.9M) | (287.4M) | (195.1M) | (154.5M) | (115.2M) |
| Non-Operating | |||||
| Interest Income | 25.3M | 28.6M | 37.2M | 13.1M | 2.9M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 25.3M | 28.6M | 37.2M | 13.1M | 2.9M |
| Other Non-Op Income/Expense | 25.3M | 28.6M | 37.2M | 13.1M | 2.9M |
| Non-Operating Income (excl Interest) | (25.3M) | (28.6M) | (37.2M) | (12.5M) | (8.1M) |
| EBT (Pre-Tax Income) | (300.6M) | (258.8M) | (157.9M) | (141.4M) | (112.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (300.6M) | (258.8M) | (157.9M) | (141.4M) | (112.3M) |
| Earnings from Cont. Ops | (300.6M) | (258.8M) | (157.9M) | (141.4M) | (112.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (300.6M) | (258.8M) | (157.9M) | (141.4M) | (112.3M) |
| Per Share | |||||
| Basic EPS | ($4.36) | ($3.90) | ($2.45) | ($2.92) | ($2.40) |
| Diluted EPS | ($4.36) | ($3.90) | ($2.45) | ($2.92) | ($2.40) |
| Revenue Per Share | $0.00 | $0.02 | $0.11 | $0.14 | $0.05 |
| Shares | |||||
| Basic Shares Outstanding | 77.8M | 66.5M | 64.4M | 48.4M | 46.9M |
| Diluted Shares Outstanding | 77.8M | 66.5M | 64.4M | 48.4M | 46.9M |
| Profitability Metrics | |||||
| EBITDA | (297.2M) | (255.4M) | (154.7M) | (139.0M) | (104.2M) |
| D&A | 3.4M | 3.4M | 3.2M | 3.0M | 2.9M |
| EBIT | (300.6M) | (258.8M) | (157.9M) | (142.0M) | (107.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026